{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:56:11Z","timestamp":1790283371116,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.euf.2023.10.016","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T05:34:56Z","timestamp":1698989696000},"page":"715-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["How to Compose Platform Trials"],"prefix":"10.1016","volume":"9","author":[{"given":"Noel W.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2023.10.016_b0005","unstructured":"STAMPEDE trial. www.stampedetrial.org."},{"key":"10.1016\/j.euf.2023.10.016_b0010","unstructured":"RECOVERY: randomised evaluation of COVID-19 recovery. www.therecoverytrial.net."},{"key":"10.1016\/j.euf.2023.10.016_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-10-39","article-title":"Issues applying multi-arm, multi-stage methodology to trials in prostate cancer: the MRC STAMPEDE trial","volume":"10","author":"Sydes","year":"2009","journal-title":"Trials"},{"key":"10.1016\/j.euf.2023.10.016_b0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06680-4","article-title":"Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units","volume":"23","author":"Love","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.euf.2023.10.016_b0025","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of prostate cancer overall survival","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2023.10.016_b0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled trial phase 3 study","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2023.10.016_b0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2023.10.016_b0040","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed metastatic prostate cancer (STAMPEDE): a randomised phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2023.10.016_b0045","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692300233X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692300233X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:55:08Z","timestamp":1762498508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545692300233X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S240545692300233X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2023.10.016","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Compose Platform Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2023.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}